Authored Content
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.
Manufacturers can accelerate innovation and improve rare and ultra-rare disease therapy access by leveraging new and established regulatory pathways.
A detailed Avalere report offers insights into state-specific statutes guiding commercial payer coverage for off-label use of oncology drugs/biologics.
Recent FDA authorization of Florida’s Section 804 Importation Program has prompted increased focus on importation pathways.